p14ARF/CDKN2A Antibody - BSA Free

Knockdown Validated: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.

Immunohistochemistry: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo and synergizes with ionizing radiation to inhibit tumor growth( Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). Sections of PSN1 xenografts and in-vitro PSN1 cells fixed and stained with anti-NPM (red) and anti-p14ARF (green). Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.

Immunocytochemistry/Immunofluorescence: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested in HeLa cells with Dylight 488 (green). Nuclei were counterstained with DAPI (blue). Tubulin was stained with alpha tubulin (red).

Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - ARF expression levels in OCI/AML3 cells after proteasome treatment. This image was submitted via customer Review.

Flow Cytometry: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested at 1:400 in HeLa cells using an Alexa Fluor 488 secondary (shown in purple). M1 is defined by unstained cells.

Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Analysis of HeLa Whole Cell Lysate (NB800-PC1) using p14ARF antibody (lot C) employing ECL detection method.

Immunohistochemistry-Frozen: p14ARF/CDKN2A Antibody [NB200-111] - Mouse brain section, hippocampal (10 um thickness). 3% PFA perfused. 1:1000 dilultion. Image from verified customer review. Image using the Biotin form of this antibody.

• Reactivity: Hu, Mu
• Applications: WB, ELISA, Flow, ICC/IF, IHC, IP, KD
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 1.0 mg/ml

p14ARF/CDKN2A Antibody - BSA Free Summary

• Immunogen: A synthetic peptide made to a portion of human p14ARF (between residues 50-150). [Swiss-Prot# Q8N726]
• Localization: Nuclear
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: CDKN2A
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • ELISA 1:100-1:2000
  • Flow Cytometry 1:400
  • Immunocytochemistry/Immunofluorescence reported in scientific literature (PMID 25071014)
  • Immunohistochemistry 1:10-1:500. Use reported in scientific literature (PMID 18505964)
  • Immunohistochemistry-Frozen 1:10-1:500. Use reported by customer review
  • Immunohistochemistry-Paraffin 1:10-1:500
  • Immunoprecipitation reported in scientific literature (PMID 20699639)
  • Knockdown Validated
  • Western Blot reported in scientific literature (PMID 21636682)
• Application Notes: This p14ARF antibody can be used for Western blotting, where a band is seen at ~16 kDa, representing p14ARF. Additional faint bands may be seen at ~32 and 47 kDa. In ICC/IF [PMID: 25071014], nuclear focal staining was observed in HeLa cells.

Reactivity Notes

Human and mouse reactivity reported in scientific literature.

Packaging, Storage & Formulations

• Storage: Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: 0.05% Sodium Azide
• Concentration: 1.0 mg/ml
• Purity: Immunogen affinity purified

Alternate Names for p14ARF/CDKN2A Antibody - BSA Free

• ARF
• CDK4 inhibitor p16-INK4
• CDK4IP14ARF
• CDKN2
• cell cycle negative regulator beta
• CMM2P16-INK4A
• Cyclin-dependent kinase 4 inhibitor A
• cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)
• cyclin-dependent kinase inhibitor 2A
• INK4
• INK4A
• MLMP16INK4
• MTS-1
• MTS1P14
• Multiple tumor suppressor 1
• p14
• p14ARF
• P16
• p16-INK4
• P16INK4A
• p16-INK4a
• P19
• P19ARF
• TP16

Background

The INK4a-ARF locus is comprised of two tumor suppressors, p16INK4a and p14ARF. These two proteins are encoded through differential splicing of alternative first exons. The p16INK4a (exon 1 alpha) protein inhibits the cyclin D-dependent kinases (CDK) that control the phosphorylation of the Rb protein and cell proliferation. The p14ARF gene product complexes with the MDM2 protein within the nucleus, thus modulating the activity of the p53 protein. P14ARF is a potent tumor suppressor in the presence of wild-type p53, while mutant p53 substantially reduces growth inhibition by p14ARF.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for p14ARF/CDKN2A Antibody (NB200-111)(17)

Publications using NB200-111

• Xiong H, Yang Y, Yang K et al. Loss of the clock gene PER2 is associated with cancer development and altered expression of important tumor-related genes in oral cancer. Int J Oncol 2018-01-01 [PMID: 29115399] (Human)
• Crawford Parks TE, Marcellus KA, Langill J et al. Novel Roles for Staufen1 in Embryonal and Alveolar Rhabdomyosarcoma via c-myc-dependent and -independent events. Sci Rep. 2017-02-17 [PMID: 28211476] (WB, Human)
• Ghosh M, Ryan RO. Curcumin homing to the nucleolus: mechanism for initiation of an apoptotic program. J Nutr. Biochem. 2014-08-01 [PMID: 25172633] (WB, Human)
• Hamilton Garth, Abraham Aswin G, Morton Jennifer et al. AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget. 2014-08-15 [PMID: 25071014] (ICC/IF)
• Williams RT, Barnhill LM, Kuo HH et al. Chimeras of p14ARF and p16: Functional Hybrids with the Ability to Arrest Growth. PLoS ONE 2014-02-07 [PMID: 24505435] (WB, Human)
• Chio II, Sasaki M, Ghazarian D, Moreno J, Done S, Ueda T, Inoue S, Chang YL, Chen NJ, Mak TW. TRADD contributes to tumour suppression by regulating ULF-dependent p19(Arf) ubiquitylation. Nat Cell Biol;14(6):625-33. 2012-05-06 [PMID: 22561347] (WB, Human, Mouse)
• Muniz V, Barnes JM, Paliwal S et al. The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis. Mol Cancer Res 9(7):867-77. 2011-07-01 [PMID: 21636682] (WB, Mouse)
• Chen D, Yoon JB, Gu W. Reactivating the ARF-p53 axis in AML cells by targeting ULF. Cell Cycle 2010-08-01 [PMID: 20699639] (IP, Human)
• Greiner T. Who chooses the leaders of UN organisations? Lancet 2010-03-27 [PMID: 20346814] (Human)
• Chen D, Shan J, Zhu WG, Qin J, Gu Wet al. Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses. Nature 2010-03-25 [PMID: 20208519] (IP, Human)
• Wang W-H, Hullinger RL, risani OM. Hepatitis B virus X protein via the p38MAPK pathway induces E2F1 release and ATR kinase activation mediating p53 apoptosis. J Biol Chem 283(37):25455-67. 2008-09-12 [PMID: 18606816] (WB, Mouse)
• Freedberg DE et al. Frequent p16-independent inactivation of p14ARF in human melanoma. J Natl Cancer Inst 100(11):784-95. 2008-06-04 [PMID: 18505964] (IF/IHC, Human)
• Mascaux, C et al. The role of NPM, p14arf and MDM2 in precursors of bronchial squamous cell carcinoma. Eur Respir J 32(3):678-86. 2008-09-01 [PMID: 18480108] (IF/IHC, Human)
• Miller SJ et al. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res 66(5):2584-91. 2006-03-01 [PMID: 16510576] (WB, Human)
• Kuo, ML et al. N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev 18(15):1862-74. 2004-08-01 [PMID: 15289458] (WB, Human, Mouse)
• Magro PG, Russo AJ, Li WW et al. p14ARF expression increases dihydrofolate reductase degradation and paradoxically results in resistance to folate antagonists in cells with nonfunctional p53. Cancer Res 2004-06-15 [PMID: 15205349] (Human)
• Fatyol, K et al. The p14ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1alpha (HIF-1alpha ) and inhibits HIF-1-mediated transcription. J Biol Chem 276(30):28421-9. 2001-07-27 [PMID: 11382768] (WB, Mouse, Human)

Reviews for p14ARF/CDKN2A Antibody (NB200-111) (2)

Average Rating: 4

(Based on 2 reviews)

We have 2 reviews tested in 1 species: Human.

reviewed by: Verified Customer WB Human 09/01/2017

Summary

• Application: Western Blot
• Sample Tested: human AML NPM cytoplasmic mutant cell line,OCI/AML3 cells
• Species: Human
• Lot: H-1

reviewed by: Verified Customer WB Human 05/29/2014

Summary

• Application: Western Blot
• Sample Tested: Young and senescent cells
• Species: Human

FAQs for p14ARF/CDKN2A Antibody (NB200-111). (Showing 1 - 2 of 2 FAQs).

1. While looking for antibodies targeting human p14ARF, I found a question: Based on the information on UniProt, human p14ARF has the length of only 132 a.a. However, the immunogen of NB200-159 is described as ... between residue 125 and the C-terminus (residue 173)..., ...between residues 100-173... for NB110-59085, and ...between residues 50-150... for NB200-111.
   • Since these antibodies were produced, UniProt has since truncated the protein sequence. These antibodies are still directed towards p14ARF and the immunogens will be updated on our website to the updated amino acid ranges. Since you won't be able to see this until this weekend or early next week, the immunogen for NB200-111 falls between amino acids 50 and 132. The immunogen for NB200-159 falls between amino acids 90 and 132 and the immunogen for NB110-59085 falls between amino acids 50 and 132.
2. Do you measure the isotype purity of NB200-111? I realize this is antigen affinity purified, and will be almost completely IgG, but do you measure for IgA/M amount by chance?
   • We unfortunately do not measure isotype purity for our products.

Bioinformatics

• Gene Symbol: CDKN2A
• Entrez:
  • 1029(Human)
• Uniprot:
  • Q8N726(Human)